Treace Medical Concepts delivered solid financial results in the second quarter of 2025, with revenue increasing by 7% year-over-year to $47.4 million. The company significantly improved its net loss by 18% and adjusted EBITDA by 58%, demonstrating progress in its strategic initiatives and expanded product portfolio.
Revenue for Q2 2025 reached $47.4 million, marking a 7% increase compared to Q2 2024.
Net loss improved by 18% to $(17.4) million in Q2 2025, down from $(21.2) million in Q2 2024.
Adjusted EBITDA improved by 58% to $(3.6) million in Q2 2025, compared to $(8.7) million in Q2 2024.
The company expanded its global patent portfolio to 117 granted patents and 163 pending patent applications.
Treace Medical Concepts reaffirmed its full-year 2025 revenue guidance and continues to expect breakeven Adjusted EBITDA for the full year.
Analyze how earnings announcements historically affect stock price performance